|
| Assaf Alon | Blavatnik Institute, Harvard Medical School |
| Jiankun Lyu | Department of Pharmaceutical Chemistry, University of California san francisco |
| Tia A Tummino | Department of Pharmaceutical Chemistry, University of California san francisco |
| Tia A Tummino | Graduate Program in Pharmaceutical Sciences and Pharmacogenomics, University of California san francisco |
| Matthew J O'Meara | University of Michigan ann arbor |
| Xi-Ping Huang | University of North Carolina at Chapel Hill School of Medicine |
| Xi-Ping Huang | National Institute of Mental Health Psychoactive Drug Screening Program (NIMH PDSP), University of North Carolina at Chapel Hill School of Medicine |
| Bryan L Roth | University of North Carolina at Chapel Hill School of Medicine |
| Bryan L Roth | Eshelman School of Pharmacy, University of North Carolina at Chapel Hill |
| Bryan L Roth | National Institute of Mental Health Psychoactive Drug Screening Program (NIMH PDSP), University of North Carolina at Chapel Hill School of Medicine |
| Bryan L Roth | University of North Carolina at Chapel Hill School of Medicine |
| Bryan L Roth | National Institute of Mental Health Psychoactive Drug Screening Program (NIMH PDSP), University of North Carolina at Chapel Hill School of Medicine |
| Bryan L Roth | Eshelman School of Pharmacy, University of North Carolina at Chapel Hill |
| John J Irwin | Department of Pharmaceutical Chemistry, University of California san francisco |
| Brian K Shoichet | Department of Pharmaceutical Chemistry, University of California san francisco |
| Brian K Shoichet | Department of Pharmaceutical Chemistry, University of California san francisco |
| Andrew C Kruse | Blavatnik Institute, Harvard Medical School |